Protocol: *S.cerevisiae* complex purification

One step TAP-Tag purification

NOTE 1: This is the one step protocol which gives great yields and has been used to purify enzyme complexes for *in vitro* functional analyses. If you want superpure samples for MS-studies uses the two step protocol (which has a much lower yield, but higher purity). I've used this protocol to purify kinases, phosphatases and HATs for *in vitro* analyses: all is the same until the dialysis buffer of choice.

Modification of protocol used in: Keogh *et al* (2006) *Genes Dev* 20:660-5.

Making extracts

- 1. Grow 1L cells in appropriate medium to $OD_{\lambda 600} < 1.0$ (exponential phase, etc). All steps below are with pre-chilled solutions on ice unless stated otherwise.
- 2. Collect cells by centrifugation. Successively wash with 100mls ddH₂O and 50mls Lysis buffer (LB°, + inhibitors; LB°+). Transfer cells to a 50ml Falcon and collect by centrifugation. Estimate the wet weight of the pellet (≈ 5 g/L for 1L culture OD_{$\lambda 600$} ≈ 1.0). Store pellets @ -80°C (stable for months).
- 3. Thaw pellet on the bench (RT°) and then place on ice. Add 5mls LB°+ and resuspend completely. Add an equal volume of glass beads and place on ice for 5-10mins to chill. Lyse with 5 x vortex pulses (1 min vortex, 1 min on ice). Centrifuge 10K, 10m, 4°C. This is done in the preparative centrifuge with the Sorvall SS-34 rotor. You can spin the 50ml Falcon in the SS-34 rotor if you do not use the lid.
- 4. Collect the straw-colored supernatant to a Beckman untracentrifuge tube (26.3ml tube) on ice. Add another 5mls LB°+ to the lysate tube and resuspend completely with another 1 min vortex. Centrifuge 10K, 10m, 4°C and pool the supernatant in the ultra tube. Balance the ultra tubes and centrifuge 45K, 30m, 4°C. Collect the supernatant to a 15ml Falcon avoiding the crap at the bottom and the lipid payer at the top.
- 5. Using the Biorad Dc assay, estimate the concentration of the extract (usually ≈10mgs/ml). Given that you can collect ≈8mls of extract this gives you ≈80mgs(ish). Note the concentration, make 1ml aliquots and store @ -80°C.

Purification

- 6. Thaw ≈12mgs WCE on ice. Make to 4mg/ml with LB°+ and dispense into 3 x 1.5ml ependorff tubes. Add 25μl IgG Agarose (Sigma, equilibrated in LB°) per tube and incubate overnight / 4°C with rotation.
- 7. Collect beads by centrifugation (1.5K, 2min, benchtop). Wash with 3 x 1ml LB°+ (NO PMSF) and pool all beads from the three ependorff tubes to one tube with 1 ml TEV buffer (TEV b°). Collect by centrifugation and remove as much supernatant as possible. Make to

final volume $\approx 200 \mu l$ with TEV b°. Remove $\approx 5 \mu l$ of the slurry to a new tube to confirm efficient digestion (before).

8. Add 8µl Jess-made rTEV (see **NOTE 2**). **NB.** This volume of rTEV is accurate for the batch available @ 5/28/05; see pH13.56. The activity of new batches will have to be determined empirically. Digest 4°C, 4h on rotator. Remove ≈5µl of the slurry to a new tube to confirm efficient digestion (after). Collect the supernatant through a Promega Wizard column. Wash beads with 40µl TEV b° and pool with supernatant.

NOTE 2: TEV, Tobacco Etch Virus NIa protease. Super expensive and available from Invitrogen (Cat# 10127-017; 1000U; 10U/µl). Protocol for making rTEV NIa protease available at http://mckeogh.googlepages.com/protocols. Each batch of rTEV should be titrated for activity. Below % substrate hydolysis data from Invitrogen.

Time	4°C	16°C	21°C	30°C
0.5h	34	58	56	77
1h	58	80	78	90
2h	71	99	99	99
3h	84	99	99	99

9. Transfer the supernatant to 2 x Slide-a-Lyzer mini dialysis units (3500MW cut-off, Pierce #69550: see NOTE 3). Dialyze for 90m, 4°C against ≈ 400ml pre-chilled buffer of choice (sample buffers for PPAses, HATs and HDACs are given below). Collect dialysate and store in aliquots at −80°C.

NOTE 3: Be careful to avoid piercing the dialysis membrane with the pipette. Ensure there's nothing suspicious about the volume in the dialysis unit (I've seen a significant number leak). To check for leaks add 100µl buffer to the unit and place it in a microfuge tube. Spin 5sec 1000rpm and discard those that allow buffer through.

Enzymatic reactions

In each case I've tested 1, 3 and 5μ l of purified complexes and shown dose-dependence. Be sure to use an untagged strain (usually YF336 / BY4741) purified in the same manner as a control. The form the template takes is obviously up to you.

HATs: (example from 1 , see MCK lab notebook pH13.57). *In vitro* HAT reactions were performed for one hour at 30° C (25μ l reactions containing 100ng histone substrates and 2μ M Acetyl CoA (Na salt, A2056 (mw 809.6); 1mg (\$15) to 1125μ l = 1mM); conditions derived from 2), resolved by 15% SDS-PAGE, and specific acetylation of Htz1-K14^{Ac} determined by immunoreactivity with a specific antibody.

Protocol: S.cerevisiae complex purification

PPAses: (example from ³). Phosphatase reactions with γH2AX/H2B substrate were performed for one hour at 30°C (conditions derived from ⁴), resolved by 15% SDS-PAGE, and relative phosphatase activity determined by immunoreactivity with anti-γH2AX.

HDACs: (#1, example from ⁵; Sin3/Rpd3). *In vitro* HAT reactions were performed for one to three hours at 30°C. 25μl reactions contain 100ng acetylated histone substrates and HDAC under test. Samples are resolved by 15% SDS-PAGE, and specific acetylation of Htz1-K14^{Ac} determined by immunoreactivity with a specific antibody.

HDACs: (#2, example from ⁶; Sin3/Rpd3). *In vitro* HAT reactions were performed for up to one hour at 37°C (do a kinetic time course: 5, 10, 20, 40, 60m). 25μl reactions contain 100ng acetylated histone substrates and HDAC under test. Samples are resolved by 15% SDS-PAGE, and specific acetylation of Htz1-K14^{Ac} determined by immunoreactivity with a specific antibody.

Buffers

LB° 20mM Tris.Cl pH 7.6

10% Glycerol 1mM EDTA 200mM KoAc 1mM DTT

Protease inhibitors as STD

Phosphatase inhibitors if desired (1M NaF = 1000x; 0.5M Na₃VO₄ = 1000x, 1M β -

Glycerophosphate = 200X)

TEV b° 50mM Tris.HCL pH 8.0

1mM DTT 0.5mM EDTA

Protease inhibitors as STD (but DO NOT ADD PMSF)

HAT b° 50mM Tris.HCL pH 8.0

10% Glycerol 10mM butyric acid

1mM DTT

1mM PMSF (+ other protease inhibitors)

HAT b° derived from ², see MCK notebook pH13.57.

PPase b° 20mM Tris.HCL pH 7.0

0.1mM EDTA 1mM DTT 0.01% Brij-35

1mM PMSF (+ other protease inhibitors)

PB1 derived from ⁴.

HDAC b° 1 20mM Tris.HCL pH 7.65

100mM NaCl 10% Glycerol

1mM PMSF (+ other protease inhibitors)

Derived from ⁵ against Sin3/Rpd3.

HDAC b° 2 10mM HEPES-KOH pH 7.8

75mM Kcl 0.1% NP40 5% Glycerol 2mM MgCl₂ 5mm DTT 0.25mg/ml BSA

1mM PMSF (+ other protease inhibitors)

Derived from ⁶ against Sin3/Rpd3 (I prefer the look of this one).

Protocol: *S. cerevisiae* complex purification (8/12/06) p5 of 5

2xSDS-PAGE b° 120mM Tris pH 6.8

2% SDS 20% Glycerol

0.2% bromophenol blue

200mM DTT

References

1. Keogh, M.-C., Mennella, T. A., Sawa, C., Berthelet, S. *et al.* The *Saccharomyces cerevisiae* histone H2A variant Htz1 is acetylated by NuA4. *Genes Dev* **20:**660-5 (2006).

- 2. Mizzen, C. A., Brownell, J. E., Cook, R. G. & Allis, C. D. in *Methods in Enzymology: Chromatin* (eds. Wasserman, P. M. & Wolffe, A. P.) (Academic Press, 1999).
- 3. Keogh, M.-C., Kim, J.-A., Downey, M., Fillingham, J. *et al.* DNA damage checkpoint recovery requires a phosphatase complex acting on γH2AX. *Nature* **439:**497-501 (2006).
- 4. Zabrocki, P., Swiatek, W., Sugajska, E., Trevelein, J. M. *et al.* The *Saccharomyces cerevisiae* type 2A protein phosphatase Pph22p is biochemically different from mammalian PP2A. *Eur J Biochem* **269**, 3372-82 (2002).
- 5. Kadosh, D. & Struhl, K. Histone deacetylase activity of Rpd3 is important for transcriptional repression *in vivo*. *Genes Dev* **12**, 797-805 (1998).
- 6. Vermeulen, M. & Stunnenberg, H. G. An *in vitro* assay to study the recruitment and substrate specificity of chromatin modifying enzymes. *Biol Proced Online* **6**, 157-62 (2004).

Modification of protocol used in:

Keogh et al (2006) Genes Dev 20:660-5.

In vitro HAT assays

Whole cell extracts (WCEs; untagged, Esa1.TAP, Gcn5.TAP or Elp3.TAP) were prepared as described (Keogh et al. 2003). Each HAT complex was affinity purified from 10mg WCE with IgG agarose (Sigma) (5μl resin / mg WCE). After overnight incubation at 4°C the bead complexes were extensively washed with Lysis Buffer (LB: 20mM Tris.Cl pH 7.6, 10% Glycerol, 200mM KoAc, 1mM EDTA, 1mM DTT + protease inhibitors), resuspended to 200μl final in TEV buffer (TB: 50mM Tris.HCL pH 8.0, 1mM DTT, 0.5mM EDTA) and complexes cleaved from the beads with recombinant TEV protease (4 hours, 4°C). The supernatant was collected, dialyzed for one hour against HAT buffer (HB: 50mM Tris.HCL pH 8.0, 10% Glycerol, 10mM butyric acid, 1mM DTT, 1mM PMSF) and stored in aliquots at –80°C. *In vitro* HAT reactions were performed for one hour at 30°C (25μl reactions containing 100ng histone substrates and 2μM Acetyl CoA; conditions derived from (Mizzen et al. 1999)), resolved by 15% SDS-PAGE, and specific acetylation of Htz1-K14 determined by immunoreactivity with anti-Htz1 K14^{Ac}.